The investigators explained that GLP-1 receptor agonists appear to be able to help resolve MASH without worsening fibrosis. Those findings have been confirmed in mouse models and in multiple studies ...

Treatment with DD01 treatment reduced hepatic steatosis by more than 50% in 4 weeks, according to phase 1 data. The Food and Drug Administration (FDA) has granted Fast Track designation to DD01 for ...

Severe hypoglycemia (low blood sugar) can cause people with diabetes to have seizures or lose consciousness, which can make it impossible to treat low blood sugar by eating or drinking something ...

The new 12-month project extends a prior two-year award for which Habegger studied mechanisms of glucagon, Glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) and ...

Each Baqsimi device includes 1 dose of glucagon and cannot be refused. The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of ...

Glucagon is a pancreatic hormone that plays a crucial role in regulating glucose and whole-body energy metabolism. In individuals with diabetes, the pancreatic alpha cells that produce glucagon are ...

People with diabetes take insulin to lower high blood sugar. However, if glucose levels plunge too low—from taking too much insulin or not eating enough sugar—people can experience hypoglycemia, which ...

Glucagon prescriptions for severe hypoglycemia in Medicaid initially decreased from 2012 to 2018 but increased between 2019 and 2023 following the introduction of newer products. Glucagon ...

In transition-age patients with childhood-onset growth hormone deficiency (GHD), peak growth hormone (GH) response to the glucagon stimulation test (GST) appeared to be influenced more by the severity ...